Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956124 | 0.85 | GAA (0.52) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL3442044 | 0.80 | TLR9 (0.44) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL7092154 | 0.80 | GAA (0.52) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL1149214 | 0.79 | GAA (0.56) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL178444 | 0.79 | GAA (0.56) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL30896660 | 0.79 | GAA (0.56) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL9385444 | 0.77 | GAA (0.54) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL26343853 | 0.77 | GAA (0.59) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL15478776 | 0.76 | GAA (0.52) | GAASMN1; SMN2CA2CA1CA9 | |
| SCHEMBL5346463 | 0.76 | GAA (0.52) | GAASMN1; SMN2CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713627-B2 | Pathogen-inactivated red blood cell compositions | CERUS CORPORATION (US) | 2017-07-25 | — | — | US | claimed |
| US-20150157665-A1 | PATHODEN-INACTIVATED RED BLOOD CELL COMPOSITIONS | CERUS CORPORATION (US) | 2015-06-11 | — | — | US | claimed |
| US-20230408490-A1 | SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATES | CERUS CORPORATION | 2023-12-21 | — | — | US | disclosed |
| US-20230263833-A1 | COMPOSITIONS AND METHODS FOR PREPARATION OF RED BLOOD CELLS | CERUS CORPORATION | 2023-08-24 | — | — | US | disclosed |
| US-20220031917-A1 | METHODS AND KITS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | MIDCAP FINANCIAL TRUST | 2022-02-03 | — | — | US | disclosed |
| CN-113271975-A | Method and kit for preparing pathogen inactivated whole blood | 塞鲁斯公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3852817-A1 | METHODS AND KITS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | Cerus Corporation (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061537-A1 | METHODS AND KITS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | CERUS CORPORATION (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3562493-A1 | COMPOSITIONS AND METHODS FOR PREPARATION OF RED BLOOD CELLS | Cerus Corporation (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3559665-A1 | SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATES | Cerus Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190321407-A1 | COMPOSITIONS AND METHODS FOR PREPARATION OF RED BLOOD CELLS | MIDCAP FINANCIAL TRUST | 2019-10-24 | — | — | US | disclosed |
| US-8900805-B2 | Quenching methods for red blood cell pathogen inactivation | CERUS CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-1838355-B1 | IMPROVED QUENCHING METHODS FOR RED BLOOD CELL INACTIVATION PROCESS | CERUS CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20110286987-A1 | QUENCHING METHODS FOR RED BLOOD CELL PATHOGEN INACTIVATION | MIDCAP FINANCIAL TRUST | 2011-11-24 | — | — | US | disclosed |
| EP-2285210-A2 | IMPROVED QUENCHING METHODS FOR RED BLOOD CELL PATHOGEN INACTIVATION | Cerus Corporation (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7655392-B2 | Reducing of undesired side reactions upon treating a red blood cell composition with a pathogen inactivating compound comprising a nucleic acid binding ligand and an electrophilic group | CERUS CORPORATION (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009126786-A2 | IMPROVED QUENCHING METHODS FOR RED BLOOD CELL PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1838355-A1 | IMPROVED QUENCHING METHODS FOR RED BLOOD CELL INACTIVATION PROCESS | Cerus Corporation (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060115466-A1 | Reducing of undesired side reactions upon treating a red blood cell composition with a pathogen inactivating compound comprising a nucleic acid binding ligand and an electrophilic group | MIDCAP FINANCIAL TRUST | 2006-06-01 | — | — | US | disclosed |
| WO-2006050328-A1 | IMPROVED QUENCHING METHODS FOR RED BLOOD CELL INACTIVATION PROCESS | CERUS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115466-A1 | Reducing of undesired side reactions upon treating a red blood cell composition with a pathogen inactivating compound comprising a nucleic acid binding ligand and an electrophilic group | CD47, APEX1, SAMHD1 | GAA 637/4885SMN1; SMN2 3328/4885CA2 930/4885 |
| US-20150157665-A1 | PATHODEN-INACTIVATED RED BLOOD CELL COMPOSITIONS | CD47, CD4, CD209 | GAA 1784/4885SMN1; SMN2 3687/4885CA2 3301/4885 |
| US-20220031917-A1 | METHODS AND KITS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | HBG1, THPO, HBG2 | GAA 339/4885SMN1; SMN2 3008/4885CA2 4305/4885 |
| US-20110286987-A1 | QUENCHING METHODS FOR RED BLOOD CELL PATHOGEN INACTIVATION | G6PD, CD47, CD14 | GAA 340/4885SMN1; SMN2 4303/4885CA2 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.